iC42 is a unique clinical research and development facility that combines quantitative mass spectrometry (drugs, drug metabolites, other small molecules and large molecules, endogenous compounds), metabolic and protein profiling technologies in a regulatory compliant environment under one roof. Our strength and emphasis lie in the assessment of vascular endothelial dysfunction markers and pediatric pharmacological solutions.


iC42 offers the following services:

We are designed and uniquely qualified to carry out the bioanalytics for complex clinical trials involving drug quantification and molecular marker strategies. In addition, iC42 carries out research and development projects including: molecular marker discovery and qualification, translational research, strategy development and the identification of molecular mechanisms. Projects range from the development and validation of assays and strategies with only a few study samples and clinical therapeutic drug monitoring to serving as the central laboratory for phase III clinical trials with more than 50 clinical centers and more than ten thousand samples- from bioanalysis to strategic research partnerships. In addition, to research and bioanalytical services, activities include consulting and interactions with regulatory agencies.

We are the source for all of your research and development needs and we look forward to collaborating with you! 

Download this pdf for a detailed list of our services: click here

Comments are closed.